Clinical Trial Detail

NCT ID NCT02928978
Title Ruxolitinib for Premalignant Breast Disease
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Julie Nangia
Indications

ductal carcinoma in situ

lobular neoplasia

Therapies

Ruxolitinib

Age Groups: adult senior

No variant requirements are available.